Results 191 to 199 of about 8,510 (199)
Some of the next articles are maybe not open access.
Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR
Acta Pharmacologica SinicaChen Hu, Cong-hua Lu, Jie Zheng, Jun Kang, Daijuan Huang, Chao He, Yihui Liu, Zhan-Rui Liu, Di Wu, Yuanyao Dou, Yimin Zhang, Cai-yu Lin, R. Han, Yong He +13 moresemanticscholar +1 more sourceLorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support
Supportive Care in CancerRyan Brown, Katie E. Smith, Mohamed Shanshal, Anastasios Dimou, Konstantinos Leventakos, Kaushal Parikh, Aaron S Mansfield, Julian R. Molina, Matthew P. Goetz, A. Jatoi, Elizabeth Cathcart-Rake +10 moresemanticscholar +1 more source
